MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
2.690
-0.110
-3.93%
After Hours: 2.800 +0.11 +4.09% 17:30 03/13 EDT
OPEN
2.810
PREV CLOSE
2.800
HIGH
3.030
LOW
2.670
VOLUME
66.88K
TURNOVER
--
52 WEEK HIGH
3.280
52 WEEK LOW
0.5100
MARKET CAP
150.38M
P/E (TTM)
-3.7017
1D
5D
1M
3M
1Y
5Y
1D
Connect Biopharma publishes corporate presentation on rademikibart IL-4Rα antibody development in asthma and COPD
Reuters · 4d ago
Connect Biopharma To Present Results Of Phase 3 Study Of Rademikibart In Moderate-To-Severe AD Conducted By Simcere In Late-Breaking Research Session At 2026 AAD Annual Meeting
Benzinga · 5d ago
Connect Biopharma to present Phase 3 rademikibart atopic dermatitis data at AAD Annual Meeting
Reuters · 5d ago
RESULTS FROM PHASE 3 STUDY OF RADEMIKIBART IN MODERATE-TO-SEVERE ATOPIC DERMATITIS TO BE PRESENTED IN THE LATE-BREAKING RESEARCH SESSION AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING
Reuters · 5d ago
Weekly Report: what happened at CNTB last week (0302-0306)?
Weekly Report · 6d ago
Most and least shorted healthcare stocks with up to $2B market cap in February
Seeking Alpha · 03/03 14:35
Connect Biopharma to Present at Leerink Partners Global Healthcare Conference
Reuters · 03/03 14:02
Weekly Report: what happened at CNTB last week (0223-0227)?
Weekly Report · 03/02 10:34
More
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.